http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
NewLink Genetics to Participate in the Jefferies 2018 Global Healthcare Conference
-
NewLink Genetics to Participate in the Jefferies 2018 Global Healthcare Conference
-
NewLink Genetics (NLNK) Says Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO
-
NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018
-
NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018
-
NewLink Genetics Reports First Quarter 2018 Financial Results
-
NewLink Genetics Reports First Quarter 2018 Financial Results
-
NewLink Genetics (NLNK) Names Matthew L. Sherman to Board
-
NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors
-
NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors
-
NewLink Genetics to Participate in Upcoming Investor Conferences
-
NewLink Genetics to Participate in Upcoming Investor Conferences
-
NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting
-
NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting
-
NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018
-
NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018
-
NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster Presentation
-
NewLink Genetics (NLNK) Reports Initial Phase 1 Data with Indoximod Plus Radiation & Chemotherapy for Pediatric Patients with Diffuse Intrinsic Pontine Glioma
-
NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Presented During AACR Plenary
-
NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Presented During AACR Plenary
-
NewLink Genetics (NLNK) to Launch Review of Clinical Programs Following Announcement by Incyte and Merck
-
NewLink Genetics Announces Review of Clinical Programs
-
NewLink Genetics Announces Review of Clinical Programs
-
NewLink Genetics Announces Participation at The H.C. Wainwright Annual Global Life Sciences Conference
-
NewLink Genetics Announces Participation at The H.C. Wainwright Annual Global Life Sciences Conference
-
NewLink Genetics (NLNK) Names Chad A. Johnson to Board
-
NewLink Genetics Appoints Chad A. Johnson to Board of Directors
-
NewLink Genetics Appoints Chad A. Johnson to Board of Directors
-
NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
-
NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
-
NewLink Genetics to Participate in Upcoming Investor Conferences
-
NewLink Genetics to Participate in Upcoming Investor Conferences
-
NewLink Genetics Reports Fourth Quarter, Year-End 2017 Financial Results and Provides Update for Indoximod Programs
-
NewLink Genetics Reports Fourth Quarter, Year-End 2017 Financial Results and Provides Update for Indoximod Programs
-
NewLink Genetics to Host Its Fourth Quarter and Year End 2017 Financial Results Conference Call on March 1, 2018
-
NewLink Genetics to Host Its Fourth Quarter and Year End 2017 Financial Results Conference Call on March 1, 2018
-
NewLink Genetics to Participate in Upcoming Investor Conferences
-
NewLink Genetics to Participate in Upcoming Investor Conferences
-
NewLink Genetics (NLNK) Announces 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
-
NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
-
NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
-
NewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference
-
NewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference
-
NewLink Genetics to Participate in Upcoming Investor Conference
-
NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children
-
NewLink Genetics (NLNK) Appoints Eugene Kennedy as CMO
-
NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer
-
NewLink Genetics to Participate in November Investor Conferences
-
NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program
-
NewLink Genetics (NLNK) Granted FDA Orphan-Drug Designation for Indoximod

